Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Facioscapulohumeral Muscular Dystrophy
Clinical Trial
NCT07038200Last updated: 12/4/2025
RNA
Avidity Biosciences, Inc.